Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma

Abstract

RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCN-amplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Park JR, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65–86.

    Article  PubMed  Google Scholar 

  2. Nakagawara A . Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 2004; 146: 233–242.

    CAS  PubMed  Google Scholar 

  3. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982-1992. Eur J Cancer 2000; 36: 901–908.

    Article  CAS  PubMed  Google Scholar 

  4. Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007; 369: 2106–2120.

    Article  CAS  PubMed  Google Scholar 

  5. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337–350.

    Article  CAS  PubMed  Google Scholar 

  6. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10: 4–12.

    Article  CAS  PubMed  Google Scholar 

  7. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111–1116.

    Article  CAS  PubMed  Google Scholar 

  8. Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, Nakagawara A . Positive auto-regulation of MYCN in human neuroblastoma. Biochem Biophys Res Commun 2009; 390: 21–26.

    Article  CAS  PubMed  Google Scholar 

  9. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 2000; 18: 1888–1899.

    Article  CAS  PubMed  Google Scholar 

  10. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 1995; 92: 5520–5524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T et al. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene 2000; 19: 4302–4307.

    Article  CAS  PubMed  Google Scholar 

  12. Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D et al. The RUNX3 gene–sequence, structure and regulated expression. Gene 2001; 279: 221–232.

    Article  CAS  PubMed  Google Scholar 

  13. Levanon D, Groner Y . Structure and regulated expression of mammalian RUNX genes. Oncogene 2004; 23: 4211–4219.

    Article  CAS  PubMed  Google Scholar 

  14. Chuang LS, Ito Y . RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605–2615.

    Article  CAS  PubMed  Google Scholar 

  15. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2012; 31: 527–534.

    Article  CAS  PubMed  Google Scholar 

  16. Lee CW, Chuang LS, Kimura S, Lai SK, Ong CW, Yan B et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol 2011; 122: 410–417.

    Article  CAS  PubMed  Google Scholar 

  17. Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI et al. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene 2012; 31: 4302–4316.

    Article  CAS  PubMed  Google Scholar 

  18. Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010; 285: 16693–16703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Inoue K, Ito K, Osato M, Lee B, Bae SC, Ito Y . The transcription factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of dorsal root ganglion neurons. J Biol Chem 2007; 282: 24175–24184.

    Article  CAS  PubMed  Google Scholar 

  20. Inoue K, Shiga T, Ito Y . Runx transcription factors in neuronal development. Neural Dev 2008; 3: 20.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM . Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759–767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nakagawara A . Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169: 107–114.

    Article  CAS  PubMed  Google Scholar 

  23. Inoue K, Ito Y . Neuroblastoma cell proliferation is sensitive to changes in levels of RUNX1 and RUNX3 protein. Gene 2011; 487: 151–155.

    Article  CAS  PubMed  Google Scholar 

  24. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003; 22: 5525–5536.

    Article  CAS  PubMed  Google Scholar 

  25. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM . Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364–1368.

    CAS  PubMed  Google Scholar 

  26. Nakagawara A . Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998; 11: 115–124.

    CAS  PubMed  Google Scholar 

  27. Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M et al. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Clin Cancer Res 2011; 17: 6681–6692.

    Article  CAS  PubMed  Google Scholar 

  28. Westermann F, Schwab M . Genetic parameters of neuroblastomas. Cancer Lett 2002; 184: 127–147.

    Article  CAS  PubMed  Google Scholar 

  29. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 2005; 25: 8097–8107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113–124.

    Article  CAS  PubMed  Google Scholar 

  31. Gustafson WC, Weiss WA . Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249–1259.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67–78.

    Article  CAS  PubMed  Google Scholar 

  33. Salghetti SE, Kim SY, Tansey WP . Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18: 717–726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Fredlund E, Ringner M, Maris JM, Pahlman S . High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094–14099.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2008; 70: 1377–1388.

    Article  Google Scholar 

  36. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A . Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000; 407: 592–598.

    Article  CAS  PubMed  Google Scholar 

  37. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102: 731–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Guo WH, Weng LQ, Ito K, Chen LF, Nakanishi H, Tatematsu M et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 2002; 21: 8351–8355.

    Article  CAS  PubMed  Google Scholar 

  39. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 2006; 26: 4474–4488.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM . The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005; 9: 327–338.

    Article  CAS  PubMed  Google Scholar 

  41. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008; 27: 441–449.

    Article  CAS  PubMed  Google Scholar 

  42. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30: 97–105.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, JSPS KAKENHI (Grant number 24249061) and a Grant from Takeda Science Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Nakagawara.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yu, F., Gao, W., Yokochi, T. et al. RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma. Oncogene 33, 2601–2609 (2014). https://doi.org/10.1038/onc.2013.221

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2013.221

Keywords

This article is cited by

Search

Quick links